Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05280769 · ClinicalTrials.gov registry record · NA
Effects of an Oral Nicotine Product in Smokeless Tobacco Users
A NA study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- NA
- Development phase
- 31
- Enrollment target
NCT05280769: Completed NA study, sponsored by Virginia Commonwealth University.
NCT05280769 is a NA study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 31 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05280769, a NA study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- NA
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purpose of this research study is to find out how three different nicotine pouches and participant's own brand of smokeless tobacco affect blood nicotine levels and how participants feel.
Primary Outcome
Blood will be taken multiple times in each session to assess the extent to which product use changes plasma nicotine levels compared to baseline
Interventions
- OTHER oral nicotine pouch - 2 mg
- OTHER oral nicotine pouch - 4 mg
- OTHER oral nicotine pouch - 8 mg
- OTHER Smokeless tobacco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2022-08-23 |
| Est. Completion | 2023-11-28 |
| Phase | NA |
What the finished NCT05280769 record still lists
NCT05280769 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 4 interventions - of which oral nicotine pouch - 2 mg is the first listed.
NCT05280769 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05280769 about?
NCT05280769 is a clinical study titled "Effects of an Oral Nicotine Product in Smokeless Tobacco Users". The purpose of this research study is to find out how three different nicotine pouches and participant's own brand of smokeless tobacco affect blood nicotine levels and how participants feel.
What is the current status of trial NCT05280769?
This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2022-08-23. Estimated completion is 2023-11-28.
What interventions are being tested in trial NCT05280769?
The interventions under investigation include: oral nicotine pouch - 2 mg (OTHER), oral nicotine pouch - 4 mg (OTHER), oral nicotine pouch - 8 mg (OTHER), Smokeless tobacco (OTHER).
Who is sponsoring clinical trial NCT05280769?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05280769's enrollment target sits among peer trials
31 1592nd of 2000 higher than 408 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI